2024-511843-24-00招募中1 期
A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natural killer cells) in patients with relapsed/refractory diffuse large B-cell lymphoma
Emercell SAS2 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2025年2月4日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 10
- 试验地点
- 2
研究概览
简要总结
暂无简介。
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 是
入选标准
- 未提供
排除标准
- 未提供
研究者
Alain Herrera
Scientific
Emercell SAS
研究点 (2)
Loading locations...
相似试验
已完成
不适用
A phase I/IIa open-label First-in-Human study to assess safety and pharmacokinetics and explore biomarker effects of topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide in subjects with cutaneous warts.cutaneous warts10014982NL-OMON41213Cutanea Life Sciences12
进行中（未招募）
不适用
A study in volunteers with cutaneous warts to assess safety and the effect of the body on topical ionic contra-viral therapy (ICVT) comprised of digoxin and furosemide.Cutaneous wartsMedDRA version: 16.1Level: HLTClassification code 10033724Term: Papilloma viral infectionsSystem Organ Class: 100000004862EUCTR2013-005569-38-NLCutanea Life Sciences
招募中
1 期
A first-in-human study evaluating the safety of AXA-042 as a single agent in patients with advanced solid tumorsAdvanced solid tumorsCancer - Any cancerACTRN12622000993796Axelia Oncology Pty Ltd18
招募中
1 期
Phase 1 First-Time-in-Human, Open-Label Study of GSK4381562 Administered to Participants with Advanced Solid TumorsSelected Advanced Solid TumorsJPRN-jRCT2031220403Ishibashi Hideyasu126
招募中
1 期
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumorsadvanced solid tumorsJPRN-jRCT2031210338Ishibashi Hideyasu184